Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
Trial ID or NCT#
This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.
Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors
- - Advanced solid tumor and that is measurable by a scan
- - Uncontrolled or untreated central nervous system metastases - Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day 1 - Any of the following cardiac conditions: - History of myocardial infarction, acute coronary syndromes up to 12 weeks before Cycle 1 Day 1 - Class III or IV heart failure up to 6 months before Cycle 1 Day 1 - Baseline heart rate corrected QT interval (QTc)> 450 msec - History of ventricular arrhythmias up to 6 months before Cycle 1 Day 1 - Use of medications that prolong the QTc interval and are associated with Torsades de Pointe (TdP) - Previous cancer treatment up to 21 days before first dose - Any investigational therapy up to 28 days before Cycle 1 Day 1 - Known allergy to cyclodextrins Please note: There are additional inclusion/exclusion criteria for this study. Please contact the study center for additional information and to determine if all study criteria are met.
Contact us to find out if this trial is right for you.